Stock Update (NASDAQ:CELG): Oral Presentation Evaluating Pooled Data on OTEZLA® (apremilast) for Long-Term Improvements in Enthesitis and Dactylitis to Be Presented at EULAR

[Business Wire] – BOUDRY, Switzerland–(BUSINESSWIRE)– Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG – News), today announced that the findings from a long-term (104-week) post-hoc analysis of pooled data from the . . . → Read More: Stock Update (NASDAQ:CELG): Oral Presentation Evaluating Pooled Data on OTEZLA® (apremilast) for Long-Term Improvements in Enthesitis and Dactylitis to Be Presented at EULAR Similar Articles: Market Update: Celgene Corporation (NASDAQ:CELG) – Celgene Corporation to Webcast at Upcoming Investor Conferences in June Company Update (NASDAQ:CELG): Celgene Announces Presentations of Investigational Studies in Solid Tumor and Blood Cancers at ASCO 2015 Company Update: Celgene Corporation (NASDAQ:CELG) – Phase II Data for Celgene’s Investigational Oral GED-0301 for Patients with Active Crohn’s Disease Published in New England Journal of Medicine